Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Fractyl begins clinical trial of Revita DMR system

Fractyl Laboratories has started the enrollment of patients in its multicenter clinical trial of Revita Duodenal Mucosal Resurfacing (DMR) system.

Revita-I trial is being carried out in Europe and South America to assess the safety and performance of the DMR system.

Revita is claimed to be the first non-invasive and implant free duodenal resurfacing procedural therapy that is designed to directly treat the digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

Fractyl Laboratories founder and CEO Dr Harith Rajagopalan said: "The Revita-1 study will expand our understanding of the safety and efficacy of the Revita DMR procedure in patients with type 2 diabetes.

"It will also guide our plans for multi-arm pivotal trials, along with data from our earlier, proof-of-concept human studies that we plan to publish this year."

According to the firm, around 10 patients were treated in the first phase of the Revita-I trial and it will enrol up to 50 patients across ten international sites.

The primary efficacy endpoint of the trial will be change in HbA1c in patients with uncontrolled type 2 diabetes, determined as having poor glucose control on oral medications and an HbA1c of 7.5% to 10%.

Fractyl will enroll up to 240 patients in a double-blinded and sham-controlled second phase of the study, which is expected to start in 2016.